3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0495TDB
  • |
  • Pages: 41
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, '3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Pipeline Review, H2 2016', provides in depth analysis on 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)

The report reviews 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Overview 6

Therapeutics Development 7

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Products under Development by Stage of Development 7

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Products under Development by Therapy Area 8

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Products under Development by Indication 9

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Pipeline Products Glance 11

Early Stage Products 11

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Products under Development by Companies 12

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Companies Involved in Therapeutics Development 19

Arno Therapeutics, Inc. 19

Sunesis Pharmaceuticals, Inc. 20

Tolero Pharmaceuticals, Inc. 21

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Drug Profiles 22

AR-12-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

HCI-1680-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

HCI-1708-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

PHT-427-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

SNS-229-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Dormant Projects 29

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)-Featured News & Press Releases 30

Nov 09, 2015: Sunesis Pharmaceuticals Presents Preclinical Data From Its PDK1 Inhibitor SNS-229 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 30

Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis 31

Oct 27, 2015: Sunesis Pharmaceuticals Announces Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 31

Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains 32

Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference 33

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 33

Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition 35

Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 35

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research 36

May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 37

Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 38

Aug 27, 2009: Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway 38

May 11, 2009: FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 18

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Arno Therapeutics, Inc., H2 2016 19

Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016 20

Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 21

Dormant Projects, H2 2016 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Arno Therapeutics, Inc.

Sunesis Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Therapeutic Products under Development, Key Players in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Therapeutics, 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Pipeline Overview, 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Pipeline, 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Pipeline Assessment

select a license

Single User License
USD 3500 INR 225260
Site License
USD 7000 INR 450520
Corporate User License
USD 10500 INR 675780

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com